Item 7.01. Regulation FD Disclosure.
On February 16, 2021, VYNE Therapeutics Inc. (the "Company") completed its
previously announced reverse stock split. As a result of the reverse stock
split, every four shares of issued and outstanding common stock was
automatically combined into one issued and outstanding share of common stock,
without any change in the par value per share. No fractional shares were issued
as a result of the reverse stock split. In lieu thereof, the Company's transfer
agent will aggregate all fractional shares and sell them as soon as practicable
at the then-prevailing prices on the open market. After the transfer agent's
completion of such sale, stockholders who would have been entitled to a
fractional share as a result of the reverse stock split will instead receive a
cash payment from the transfer agent in an amount equal to their respective pro
rata share of the total proceeds of that sale. If stockholders have any
questions regarding fractional shares, they should contact the transfer agent,
American Stock Transfer & Trust, at 877-248-6417 (toll free).
Following the reverse stock split, there are now 51,326,891 shares of common
stock issued and outstanding.
The information being furnished pursuant to this "Item 7.01 Regulation FD
Disclosure" shall not be deemed to be "filed" for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
otherwise subject to the liabilities of that section and shall not be deemed to
be incorporated by reference into any filing under the Securities Act of 1933,
as amended, or the Exchange Act regardless of any general incorporation language
in such filing.
© Edgar Online, source Glimpses